BLS Pharmaceuticals Limited has updated its corporate governance policies, focusing on ethical conduct, whistleblower protection, and risk management. The company has disclosed its values and ethical business conduct in its Code of Conduct, available on the Corporate Governance page of its website. BLS also has a whistleblower policy and an anti-bribery and corruption policy, both of which are disclosed and require material incidents and breaches to be reported to the board via the Chair.
Material actions and disclosures
BLS has a diversity and equal opportunity policy, committed to developing a diverse workforce. However, specific measurable objectives for achieving gender diversity have not yet been set due to the current small number of employees. The company’s board evaluates its performance annually, comparing it against the requirements of its charter and making necessary improvements.
The company does not have an internal audit function but has established a Risk Management Policy to manage material business risks. The policy is reviewed annually by senior management and the board.
Forward commitments
BLS plans to set measurable objectives for achieving gender diversity when the company employs sufficient employees to enable relevant and meaningful objectives to be achieved.